Janux Therapeutics (NASDAQ:JANX) Reaches New 52-Week Low – Time to Sell?

05 Feb 2026, 13:50 by Renee Jackson · The Cerbat Gem

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) hit a new 52-week low on Thursday . The stock traded as low as $12.72 and last traded at $12.8310, with a volume of 445755 shares trading hands. The stock had previously closed at $13.33.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. UBS Group reiterated a “buy” rating and issued a $57.00 price target on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Wedbush reissued an “outperform” rating and issued a $45.00 price target (down previously from $76.00) on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. Piper Sandler reduced their price objective on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a research note on Friday, January 16th. Bank of America reduced their target price on Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, December 2nd. Finally, Clear Str lowered shares of Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Eleven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $60.08.

View Our Latest Research Report on Janux Therapeutics

Janux Therapeutics Stock Performance

The firm’s 50-day simple moving average is $15.61 and its two-hundred day simple moving average is $22.06. The stock has a market cap of $757.59 million, a price-to-earnings ratio of -7.49 and a beta of 2.88.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.07 million. Equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Transactions at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 1,879 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $25,798.67. Following the sale, the insider owned 83,095 shares of the company’s stock, valued at approximately $1,140,894.35. This trade represents a 2.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Zachariah Mciver sold 2,714 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $37,263.22. Following the sale, the insider owned 23,286 shares in the company, valued at $319,716.78. This trade represents a 10.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 25,699 shares of company stock valued at $471,235. Corporate insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. DNB Asset Management AS boosted its position in Janux Therapeutics by 93.7% during the fourth quarter. DNB Asset Management AS now owns 17,274 shares of the company’s stock worth $238,000 after purchasing an additional 8,355 shares during the period. UBS Group AG boosted its holdings in Janux Therapeutics by 51.2% in the 4th quarter. UBS Group AG now owns 590,060 shares of the company’s stock valued at $8,143,000 after purchasing an additional 199,703 shares during the period. Teachers Retirement System of The State of Kentucky acquired a new stake in Janux Therapeutics during the fourth quarter worth approximately $536,000. FNY Investment Advisers LLC grew its holdings in shares of Janux Therapeutics by 97.7% during the 4th quarter. FNY Investment Advisers LLC now owns 10,300 shares of the company’s stock worth $142,000 after purchasing an additional 5,090 shares in the last quarter. Finally, Congress Asset Management Co. grew its stake in Janux Therapeutics by 2.8% during the fourth quarter. Congress Asset Management Co. now owns 57,342 shares of the company’s stock worth $791,000 after buying an additional 1,569 shares in the last quarter. 75.39% of the stock is owned by institutional investors.

About Janux Therapeutics

(Get Free Report)

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.